Markets open

Gilead Sciences, Inc.

GILD · Nasdaq

Analyst Consensus

Buy

24 analysts

$132

Current

—

Low

$162

Average

—

High

Average target implies +23.10% versus the current price.

The ratings synthesis for GILD has not been generated yet.

Rating Actions

No individual rating actions have been captured for GILDyet. Consensus figures above come from Nasdaq's aggregate feed.

Rating actions are extracted from published reporting. Each row links to its source.

Covering Firms

B OF A GLBL RES

BAIRD R W

BARCLAYS CAPITA

BMO CAPITAL MKT

CANTOR FITZGERA

CO FORECST

DBS BANK

DEUTSCHE BK SEC

EDWARD JONES

HSBC GLOBAL RES

JEFFERIES & CO.

JP MORGAN SECUR

LEERINK PARTNRS

MAXIM GROUP,LLC

MIZUHO SECURITI

MORGAN STANLEY

OPPENHEIMER HLD

PIPER SANDLER

RAYMOND JAMES

RBC CAPITAL

TD COWEN

TRUIST SECURITI

WELLS FARGO SEC

ZACKS RESEARCH

Symbol: GILD
Type: Stock
Sector: Health Care
Industry: Biotechnology: Biological Products (No Diagnostic Substances)
Country: North America
Exchange: Nasdaq

Gilead Sciences, Inc. is a biopharmaceutical company that has pursued and achieved breakthroughs in medicine for more than three decades, with the goal of creating a healthier world for all people. The company is committed to advancing innovative medicines to prevent and treat life-threatening diseases, including HIV, viral hepatitis, COVID-19, cancer and inflammation. Gilead operates in more than 35 countries worldwide, with headquarters in Foster City, California.